Managing Mounjaro (Tirzepatide)-Induced Nausea

First-Line Antiemetic Management

The American College of Physicians recommends metoclopramide 10-20 mg orally as the primary treatment approach for medication-induced nausea, supported by the strongest evidence for nonspecific nausea 1, 2
The National Comprehensive Cancer Network suggests prochlorperazine 10 mg orally every 6 hours as an alternative phenothiazine option for patients with tirzepatide-induced nausea 1
Haloperidol 0.5-1 mg orally every 6-8 hours is recommended for patients who don't respond to first-line agents, according to the National Comprehensive Cancer Network 1

The National Comprehensive Cancer Network recommends administering antiemetics around the clock for 1 week rather than as-needed dosing for patients with persistent nausea 1
Adding 5-HT3 receptor antagonists (ondansetron or granisetron) to the dopamine antagonist for synergistic effect is suggested by the National Comprehensive Cancer Network, rather than switching medications 1, 2
The combination approach (metoclopramide plus ondansetron) provides superior relief for persistent nausea, according to the National Comprehensive Cancer Network 1

The National Comprehensive Cancer Network highly recommends prophylactic antiemetic treatment before starting tirzepatide for patients with prior history of medication-induced nausea 1
Prochlorperazine or metoclopramide can be used prophylactically, according to the National Comprehensive Cancer Network 1

The National Comprehensive Cancer Network suggests ruling out other causes of nausea, such as constipation, before attributing it solely to tirzepatide 1, 2
Gastroesophageal reflux should be considered and treated with proton pump inhibitors or H2 receptor antagonists, according to the National Comprehensive Cancer Network 2
Proper nausea management can prevent premature discontinuation and maintain treatment adherence, as recommended by the National Comprehensive Cancer Network 1